Factors such as the
rising prevalence of infectious diseases and the introduction of newer
pathogens, the need for prompt diagnosis, the increasing number of blood
transfusions and donations, and the cost-benefits of INAAT are the key factors
driving the market growth.
The Isothermal Nucleic Acid Amplification Technology Market is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period.
Market
Segmentations:-
Based on the product,
the INAAT market is segmented into assay, kits, and reagents,
and systems. Assay, kits, and reagents segment are expected to account for the
largest share of the INAAT industry in 2019, Based on the type, the global
market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies.
Based on application,
the INAAT market is segmented into infectious disease diagnosis, blood
screening, and other applications such as cancer diagnosis, cancer research,
and laboratory research, which encompass cDNA preparation, whole-genome
amplification (WGA), single-nucleotide polymorphism (SNP), and mutation
analysis.
Based on the end user,
the market is divided into hospitals, reference laboratories, academic and
research institutes, and other end users.
Regional
Analysis:-
In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe.
Top
Key Players:-
The major companies in
the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US),
Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and
Meridian Bioscience (US).